Teva Appoints John Nason President of Growing Biologics Operations
Teva promotes John Nason to President, Teva Active Pharmaceutical Ingredients (TAPI) and Biologics Operations, a role with growing importance as biologics has become an integral part of the generic pharma company’s long-term growth strategy. Teva is the leading worldwide supplier of these drugs, and Nason will be responsible for the development, manufacturing, marketing, and sales.
“John’s deep technical expertise and strong track record distinguish him as a global leader who is exceptionally qualified for this pivotal role,” said Carlo de Notaristefani, Executive Vice President, Teva Global Operations, in a statement.
Nason joined Teva in 2015 as Senior Vice President of European Technical Operations and was previously a senior leader of Bristol-Myers Squibb’s API operations for 12 years.
Agios Pharmaceuticals Names Wall Street Guru Jacqualyn Fouse CEO
Former Celgene executive, Jacqualyn Fouse, has joined the Massachusetts-based cancer specialists as their new Chief Executive Officer. Fouse will replace David Schenkein as he ends his 10-year run as Agios CEO.
“Throughout her career, Jackie has demonstrated the ability to effectively plan for and successfully execute on clinical and commercialization strategies, which will be essential as the company works to further its transition to a sustainable multi-product company,” Agios Chairman John Maraganore said in a statement.
Fouse has plans to address marketing opportunities outside the U.S., build a strategy for expanding commercialization of existing products, and bring in new drugs from the outside through licensing deals or acquisitions for the first time.
Celgene and Agios have been oncology partners for years, familiarizing Fouse with the company’s dealings before taking a position on the Agios Board last December.
Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors as the company prepares for its next phase of growth and development. Pappas brings more than 30 years of experience as a pharmaceutical and biotechnology industry executive. He is also the Founder and Managing Partner of Pappas Capital, a leading U.S. venture firm.
The healthcare service provider appoints life sciences veteran Pierre van Weperen as Commercial and Patient Solutions U.K. Managing Director. With 17 years of experience, he will lead the commercial team as it provides contract sales services to pharma companies across Europe, as well as the Patient Solutions department, which designs and delivers nurse-led patient support services.
Cello Health Communications
Former Senior Director of Corporate Communications, EMEA at Astellas, Jo Taylor, takes up the position of Head of Corporate Affairs at the global communications agency. With her 25 years of experience, Taylor will lead a team to shape positive environments for the uptake of new medicines as well as public policy, government affairs, corporate and brand communications, market access, employee engagement, sustainability, pricing, and health technology.
The market access advertising agency taps Bristol-Myers Squibb veteran Jill Cantelmo, PhD, MSc to serve as SVP, Health Economics and Content Strategy. Previously serving as the global Publication and Scientific Content team for BMS, Dr. Cantelmo will use her experience to shift Cyan towards HEOR as a pillar of the market access value equation.
Laura Hamill joins the company as Executive Vice President, Worldwide Commercial Operations. As the new manager of commercial operations, she will drive strategic planning, deliver operating results, execute product launches and strategic partnerships, and lead market development. Hamill will leave Amgen where she most recently served as Senior Vice President, U.S. Commercial Operations.
Chris Corsico, former Chief Medical Officer at Boehringer Ingelheim, joins the pharma giant as Head of Drug Development. Corsico leaves his 20-year career at Boehringer Ingelheim to directly oversee development in the U.K. as well as Philadelphia for research focused on identifying and prosecuting novel immunology and genetically validated targets with new and innovative technologies.
The health communications consultancy names John Watson its Creative Lead to further its global creative capabilities and to inspire and create imaginative solutions to solving complex health challenges. Watson brings over 25 years of experience from agencies including Ogilvy Healthworld and Publicis LifeBrands.
Health Strategies Group
The leader in market access intelligence and research for pharma and biotech expands its global market access team with the appointment of Anita Burrell as Vice President and Practice Lead for Global Market Access. Burrell will be focusing on the interdependencies of pricing and reimbursement policies, in which she’s had extensive experience, including in her leadership roles at Sanofi.
The rapidly expanding pharma marketing agency announces the promotion of Stewart Young to Vice President of Strategic Planning. Previously a Group Director of Strategic Planning, Young will now help the team continue to grow and make a valued difference for clients and internal agency partners.
Con Franklin takes over the role of Managing Director of Healthcare in Ketchum’s London office as Kate Paxton ends her tenure and returns to the U.S. headquarters. With 17 years of experience, most recently serving at FTI Consulting, Franklin will now be responsible for growing Ketchum’s healthcare business and developing new talent.
The biotech startup that created the first miniature beating hearts from stem cells appoints Bernard Fermini, PhD as Chief Research & Development Officer. Dr. Fermini has served Pfizer for 17 years, overseeing collaboration between Novoheart and Pfizer to create mini hearts with Friedreich’s ataxia (FRDA) in order to accurately test the effectiveness of new drug candidates on the specific disease.
The Cambridge, MA-based biopharma company taps Roche’s previous Senior Vice President and Global R&D Head, Dr. Sanjay Keswani as their new CEO. Dr. Keswani will guide Rheos towards targeting the underlying cellular metabolism of immune cells and unique biomarkers to treat a wide range of immune-mediated diseases and cancer.